Lundbeck VYEPTI Study Shows Cognitive Symptom Improvements

Lundbeck Delivers Promising Real-World Evidence for VYEPTI in Treatment-Resistant Migraine Patients

Copenhagen-based pharmaceutical company H. Lundbeck announced significant clinical findings on April 19, 2026, revealing how VYEPTI (eptinezumab) addresses a particularly troubling symptom that often goes overlooked in migraine treatment discussions: cognitive dysfunction. The company presented data from its INFUSE study at the American Academy of Neurology’s 2026 annual conference, offering what researchers describe as the first real-world evidence examining migraine-related cognitive symptoms in patients who had previously failed other anti-CGRP (calcitonin gene-related peptide) therapies.

The INFUSE Study: Bridging the Gap in Migraine Care

The INFUSE trial represents a critical examination of an underserved patient population—those whose migraines have proven resistant to existing anti-CGRP medications. Rather than relying solely on controlled clinical environments, the study tracked actual patient experiences across a full year, documenting baseline cognitive symptoms and measuring changes over a six-month treatment period. This real-world approach provides clinicians and patients with practical insights into what they can genuinely expect when switching treatment strategies.

Migraine-related cognitive symptoms, often referred to as “migraine brain fog,” represent a significant quality-of-life burden that extends far beyond the pain experience itself. Patients frequently report difficulties with concentration, memory lapses, and mental clarity during both acute migraine episodes and between attacks. These cognitive effects can substantially impact workplace productivity, personal relationships, and overall functional capacity—yet they frequently receive minimal attention in clinical conversations focused primarily on headache frequency and severity.

Understanding the Anti-CGRP Treatment Landscape

The anti-CGRP monoclonal antibody class of medications has revolutionized migraine management over the past several years, offering significantly better efficacy than traditional preventive approaches for many patients. However, not every patient responds equally to these therapies. Some individuals experience inadequate symptom relief or develop tolerance over time, necessitating either dose adjustments or treatment switches. Understanding how alternative anti-CGRP agents perform in these challenging scenarios has become increasingly important as the class has expanded.

VYEPTI, administered via quarterly intravenous infusion, operates within this anti-CGRP framework but offers a distinct pharmacological profile and delivery mechanism compared to other agents in its class. For patients dissatisfied with their current therapy, exploring whether a different anti-CGRP approach might yield better results represents a critical clinical question. The INFUSE study specifically addresses this scenario, examining what happens when treatment-resistant patients transition to VYEPTI.

Real-World Evidence Meets Patient Outcomes

The distinction between randomized controlled trials and real-world evidence studies carries substantial weight in modern medicine. While traditional clinical trials offer rigorous control and standardization, they often involve highly selected patient populations and carefully monitored conditions that may not reflect typical clinical practice. Real-world evidence studies, conversely, capture the messy reality of actual patient care—including treatment adherence challenges, comorbid conditions, concomitant medications, and the subtle variations that distinguish clinical textbooks from everyday practice.

By conducting the INFUSE study as a real-world evidence initiative, Lundbeck has generated data reflecting how VYEPTI actually performs when prescribing neurologists and patients implement it in their typical clinical settings. This approach provides particularly valuable information for the subset of migraine patients who have already exhausted other anti-CGRP options, a group that might otherwise lack evidence-based guidance about their next therapeutic steps.

The Cognitive Dimension of Migraine Management

While headache reduction remains the primary objective in migraine treatment, the cognitive symptom improvements documented in the INFUSE study underscore a broader shift in how the field conceptualizes migraine management. Modern migraine care increasingly acknowledges that patients suffer from far more than periodic head pain—they contend with systemic neurological dysfunction that permeates multiple domains of their lived experience.

Cognitive improvements may prove particularly consequential for working-age patients, students, and others whose economic livelihoods depend on sustained mental performance. A patient who achieves a modest reduction in migraine frequency but simultaneously experiences clearer thinking and better concentration may regard that outcome as genuinely transformative, even if headache-focused metrics show only modest gains.

Implications for Treatment Selection and Patient Counseling

The INFUSE findings contribute essential information to shared decision-making conversations between neurologists and their migraine patients. For individuals experiencing inadequate responses to their current anti-CGRP therapy, these real-world data points provide concrete evidence that switching to VYEPTI represents a reasonable consideration. The specific documentation of cognitive symptom improvements adds a dimension to treatment conversations that often receives insufficient emphasis.

Lundbeck’s presentation of these findings at the American Academy of Neurology conference ensures that the data reaches the neurologist community most directly responsible for implementing treatment recommendations. As the field continues evolving toward more personalized, targeted approaches to migraine management, this real-world evidence contributes meaningfully to the expanding knowledge base guiding clinical decision-making.